TY - JOUR
T1 - Therapeutic outcomes of transplantation of amniotic fluid-derived stem cells in experimental ischemic stroke
AU - Tajiri, Naoki
AU - Acosta, Sandra
AU - Portillo-Gonzales, Gabriel S.
AU - Aguirre, Daniela
AU - Reyes, Stephanny
AU - Lozano, Diego
AU - Pabon, Mibel
AU - Peña, Ike Dela
AU - Ji, Xunming
AU - Yasuhara, Takao
AU - Date, Isao
AU - Solomita, Marianna A.
AU - Antonucci, Ivana
AU - Stuppia, Liborio
AU - Kaneko, Yuji
AU - Borlongan, Cesar V.
PY - 2014/8/13
Y1 - 2014/8/13
N2 - Accumulating preclinical evidence suggests the use of amnion as a source of stem cells for investigations of basic science concepts related to developmental cell biology, but also for stem cells' therapeutic applications in treating human disorders. We previously reported isolation of viable rat amniotic fluid-derived stem (AFS) cells. Subsequently, we recently reported the therapeutic benefits of intravenous transplantation of AFS cells in a rodent model of ischemic stroke. Parallel lines of investigations have provided safety and efficacy of stem cell therapy for treating stroke and other neurological disorders. This review article highlights the need for investigations of mechanisms underlying AFS cells' therapeutic benefits and discusses lab-to-clinic translational gating items in an effort to optimize the clinical application of the cell transplantation for stroke.
AB - Accumulating preclinical evidence suggests the use of amnion as a source of stem cells for investigations of basic science concepts related to developmental cell biology, but also for stem cells' therapeutic applications in treating human disorders. We previously reported isolation of viable rat amniotic fluid-derived stem (AFS) cells. Subsequently, we recently reported the therapeutic benefits of intravenous transplantation of AFS cells in a rodent model of ischemic stroke. Parallel lines of investigations have provided safety and efficacy of stem cell therapy for treating stroke and other neurological disorders. This review article highlights the need for investigations of mechanisms underlying AFS cells' therapeutic benefits and discusses lab-to-clinic translational gating items in an effort to optimize the clinical application of the cell transplantation for stroke.
KW - Cerebral ischemia
KW - Neural stem/progenitor cells
KW - Neurogenesis
KW - Neurotrophic factors
KW - Regenerative medicine
UR - http://www.scopus.com/inward/record.url?scp=84939448443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939448443&partnerID=8YFLogxK
U2 - 10.3389/fncel.2014.00227
DO - 10.3389/fncel.2014.00227
M3 - Review article
AN - SCOPUS:84939448443
SN - 1662-5102
VL - 8
JO - Frontiers in Cellular Neuroscience
JF - Frontiers in Cellular Neuroscience
IS - AUG
M1 - 227
ER -